 Forma Therapeutics Holdings Inc NASDAQ: FMTX announced new data from its ongoing Phase 1 trial of etavopivat FT-4202 in sickle cell disease. Data were presented at the Annual European Hematology Association EHA 2021 Virtual Congress. 